Drug Profile
Research programme: tumour growth factor inhibitors - Apoxis
Alternative Names: APRIL inhibitorsLatest Information Update: 23 Nov 2006
Price :
$50
*
At a glance
- Originator Apoxis
- Developer Biogen Idec
- Class
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
- 02 Jul 2003 Preclinical trials in Cancer in Switzerland (unspecified route)